ClinicalTrials.gg
TerminatedNCT04912063Updated Feb 26, 2024

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

A Phase 1 interventional study of Lemzoparlimab and Azacitidine in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), sponsored by AbbVie. Terminated at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Strategic considerations

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 9 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.

Enrollment
22nd of 32
40 · median 62
Started
2021
with 3 others
Phase 1
16 of 43
1 open now
Registered
31st of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 22nd largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 1, and was the 31st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by AbbVie, or all of them as a file.
02

Study summary

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how safe lemzoparlimab is and how it moves within the body when used along with azacitidine and/or venetoclax in adult participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Adverse events and maximum tolerated dose (MTD) of lemzoparlimab will be assessed.

Lemzoparlimab (TJ011133) is being evaluated in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia (AML) and with azacitidine with/without venetoclax for myelodysplastic syndrome (MDS). Study doctors place the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of AML or MDS will be enrolled. Around 80 participants will be enrolled in the study in approximately 50 sites worldwide.

Participants will receive lemzoparlimab (IV) once weekly (Q1W), venetoclax oral tablets once daily (QD) for 28 days (AML participants) or 14 days (MDS participants) and Azacitidine by SC or IV route QD for 7 days of each 28-day cycle.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)

Keywords

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Lemzoparlimab
  • TJ011133
  • ABBV-IMAB-TJC4
  • Venetoclax
  • ABT-199
  • GDC-0199
  • VENCLEXTA
  • VENCLYXTO
  • Azacitidine
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented confirmation of acute myeloid leukemia (AML) according to the World Health Organization (WHO) criteria, previously untreated [OR]
  • Documented diagnosis of previously untreated de novo myelodysplastic syndrome (MDS) according to the 2017 WHO classification with presence of \< 20% bone marrow blasts per marrow /aspirate.
  • Participants with documented MDS must meet the following disease activity criteria:

    • Overall revised international prognostic scoring system (IPSS-R) score > 3 (intermediate, high, or very high);
    • (ECOG) performance status of 0 to 2;
    • Hematopoietic stem cell transplant () ineligible, or participant who chooses not to undergo HSCT.
  • Participants with documented AML with adverse cytogenetic and/or molecular risk, and must be considered ineligible for induction therapy defined by the following:

    • >= 75 years of age; [OR]
    • >= 18 to 74 years of age with at least one of the following comorbidities: --- Eastern cooperative oncology group (ECOG) performance status of 2 to 3; --- Cardiac history of congestive heart failure requiring treatment or \<= 50% or chronic stable angina;

      • Diffusion capacity of lung (DLCO) \<= 65% or forced expiratory volume during the first second () \<= 65%;
      • >= 30 mL/min to \< 45 mL/min;
      • Moderate hepatic impairment with total > 1.5 to \<= 3.0 × (ULN);
      • Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy or the participant declines to receive intensive chemotherapy.

Japan Safety Lead-In Phase:

  • Documented confirmation of AML according to WHO criteria, (R/R) disease without other standard of care treatments.
  • Documented diagnosis of MDS according to the 2017 WHO classification with presence of \< 20% bone marrow blasts per marrow biopsy/aspirate, with intermediate- and high-risk relapsed/refractory MDS.
  • Documented MDS must meet the following disease activity criteria:

    • ECOG performance status of 0 to 2.

Exclusion criteria

Exclusion Criteria:

  • Participants with documented AML with acute promyelocytic leukemia and considered eligible for induction therapy.
  • Participant with documented AML having prior diagnosis of:

    -- known active central nervous system involvement with AML.

  • Participants with documented MDS having prior diagnosis of:

    • MDS evolving from a pre-existing myeloproliferative neoplasm (MPN);
    • MDS/MPN including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia and unclassifiable MDS/MPN.
  • History of HSCT or solid organ transplantation.
  • Previous exposure to anti-7 therapies.
  • History of an active within the past 2 years prior to Screening, with the exception of:

    -- Adequately treated carcinoma in situ of the cervix uteri or carcinoma in situ of the breast;

    • Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin;
    • Asymptomatic prostate cancer without known disease and with no requirement for therapy;
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  • Conditions that could interfere with drug absorption including but not limited to short bowel syndrome.

Japan Safety Lead-In Phase:

  • Documented AML have Acute Promyelocytic Leukemia.
  • Participant with documented AML having prior diagnosis of:

    -- Chronic myeloid leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.

  • Participants with documented MDS having prior diagnosis of:

    • Therapy-related MDS.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)

    Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.

    Drug: Lemzoparlimab · Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)

    Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).

    Drug: Lemzoparlimab · Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    Lemzoparlimab + Azacitidine in MDS (Escalation)

    Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).

    Drug: Lemzoparlimab · Drug: Azacitidine

  • Experimental
    Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)

    Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.

    Drug: Lemzoparlimab · Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)

    Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).

    Drug: Lemzoparlimab · Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    Lemzoparlimab Monotherapy in AML (Japan Only Escalation)

    Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.

    Drug: Lemzoparlimab

  • Experimental
    Lemzoparlimab Monotherapy in MDS (Japan Only Escalation)

    Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).

    Drug: Lemzoparlimab

Interventions

  • Intravenous (IV) Infusion

    Also known as: TJ011133, ABBV-IMAB-TJC4

  • Subcutaneous Injection or Intravenous (IV) Injection/Infusion

  • Oral Tablet

    Also known as: Venclexta, Venclyxto, ABT-199, GDC-0199

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) When Co-administered With Venetoclax and Azacitidine in Participants With Treatment-Naïve Acute Myeloid Leukemia (AML) Ineligible for Standard Induction Therapy

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.

    Time frame: Up to 30 days after first dose of study drug

  2. DLTs of Lemzoparlimab (TJ011133) When Co-administered With Azacitidine With or Without Venetoclax in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndrome (MDS)

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.

    Time frame: Up to 30 days after first dose of study drug

  3. Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) as a Monotherapy in Japanese Participants with Relapsed/Refractory (R/R) AML

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.

    Time frame: Up to 30 days after first dose of study drug

  4. DLTs of Lemzoparlimab (TJ011133) as a Monotherapy in Japanese Participants with R/R MDS

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.

    Time frame: Up to 30 days after first dose of study drug

Secondary outcomes

  1. Best Overall Response of Complete Remission (CR) for AML

    Best overall response of complete remission (CR), defined as achieving CR according to modified international working group (IWG) 2003 criteria for AML.

    Time frame: Up to approximately 3 years

  2. Best Overall Response of Composite CR (CRc) for AML

    Best overall response of composite CR (CRc), \[CR or CR with incomplete blood count recovery (CRi)\] according to modified IWG 2003 criteria for AML.

    Time frame: Up to approximately 3 years

  3. Best Overall Response of CR or Complete Remission With Partial Hematologic Recovery (CRh) for AML

    Best overall response of CR or CRh, defined according to modified IWG 2003 criteria for AML.

    Time frame: Up to approximately 3 years

  4. Duration of Response (DOR) for AML

    Duration of response (DOR), defined for participants who achieve a best overall response, as the time from the first occurrence of response to disease progression/relapse from CR, CRi or CRh or death from disease progression, whichever occurs first.

    Time frame: Up to approximately 3 years

  5. Event-Free Survival (EFS) for AML

    Event-free survival (EFS), defined as time from first dose of any study drug (lemzoparlimab or venetoclax or azacitidine) to the date of progressive disease (PD), relapse from CR or CRi, treatment failure defined as failure to achieve CR, CRi or MLFS after at least 6 cycles of study treatment, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

  6. Overall Survival (OS ) for AML

    Overall survival (OS), defined as the time from the date of the first dose of any study drug (lemzoparlimab or venetoclax or azacitidine) to death from any cause.

    Time frame: Up to approximately 3 years

  7. Best Overall Response of CR, for MDS

    Best overall response of CR per the modified IWG 2006 criteria for MDS.

    Time frame: Up to approximately 3 years

  8. Best Overall Response of Marrow-Complete Remission (mCR), for MDS

    Best overall response of marrow-complete remission (mCR), per the modified IWG 2006 criteria for MDS.

    Time frame: Up to approximately 3 years

  9. Best Overall Response of CR or PR for MDS

    Best overall response of CR or PR, per the modified IWG 2006 criteria for MDS.

    Time frame: Up to approximately 3 years

  10. Best Overall Response of CR or PR or mCR, for MDS

    Best overall response of CR or PR or mCR, per the modified IWG 2006 criteria for MDS.

    Time frame: Up to approximately 3 years

  11. Hematologic Improvement (HI), for MDS

    Hematologic improvement (HI), defined as a participant achieving erythroid/platelet/neutrophil responses.

    Time frame: Up to approximately 3 years

  12. Red Blood Cell Transfusion Independence (TI), for MDS

    Red blood cell transfusion independence (TI), defined as a participant who is transfusion dependent at baseline achieved TI post-baseline.

    Time frame: Up to approximately 3 years

  13. Platelet TI, for MDS

    Platelet TI, defined as a participant who is transfusion dependent at baseline achieved TI post-baseline.

    Time frame: Up to approximately 3 years

  14. DOR, for MDS

    DOR, defined for participants who achieve a best overall response, as the time from the first occurrence of response (CR or mCR or PR) to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 3 years

  15. Progression Free Survival (PFS), for MDS

    Progression Free Survival (PFS) defined as the time from the date of the first dose of any study drug to PD or death from any cause.

    Time frame: Up to approximately 3 years

  16. OS, for MDS

    OS, defined as the time from the date of the first dose of any study drug to death from any cause.

    Time frame: Up to approximately 3 years

07

Study locations

29 sites
  • University of Alabama at Birmingham - Main /ID# 227071
    Birmingham, Alabama 35233, United States
  • Norton Cancer Institute - St Matthews /ID# 228378
    Louisville, Kentucky 40207, United States
  • Massachusetts General Hospital /ID# 227273
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center /ID# 231083
    Boston, Massachusetts 02215-5400, United States
  • University of Michigan /ID# 227030
    Ann Arbor, Michigan 48109, United States
  • University of Pennsylvania /ID# 227024
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Hillman Cancer Ctr /ID# 228048
    Pittsburgh, Pennsylvania 15232, United States
  • MD Anderson Cancer Center at Texas Medical Center /ID# 227019
    Houston, Texas 77030-4000, United States
  • University of Virginia Health /ID# 227363
    Charlottesville, Virginia 22908, United States
  • Liverpool Hospital /ID# 227723
    Liverpool, New South Wales 2170, Australia
  • Austin Health /ID# 227717
    Heidelberg, Victoria 3084, Australia
  • Marien Hospital Duesseldorf /ID# 227751
    Duesseldorf, Nordrhein-Westfalen 40479, Germany
  • Universitaetsklinikum Leipzig /ID# 227750
    Leipzig, Sachsen 04103, Germany
  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 227749
    Dresden, 01307, Germany
  • Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 227748
    Hamburg, 20246, Germany
  • The Chaim Sheba Medical Center /ID# 227389
    Ramat Gan, Tel-Aviv 5265601, Israel
  • Tel Aviv Sourasky Medical Center /ID# 227387
    Tel Aviv-Yafo, Tel-Aviv 6423906, Israel
  • Hadassah Medical Center-Hebrew University /ID# 227275
    Jerusalem, Yerushalayim 91120, Israel
  • Rabin Medical Center /ID# 227738
    Petakh Tikva, 4941492, Israel
  • Istituto Clinico Humanitas /ID# 226948
    Rozzano, Milano 20089, Italy
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 226950
    Bologna, 40138, Italy
  • ASST Grande Ospedale Metropolitano Niguarda /ID# 226952
    Milano, 20162, Italy
  • National Cancer Center Hospital East /ID# 232498
    Kashiwa-shi, Chiba 277-8577, Japan
  • University of Fukui Hospital /ID# 232466
    Yoshida-gun, Fukui 910-1193, Japan
  • Kyushu University Hospital /ID# 232564
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Yamagata University Hospital /ID# 232451
    Yamagata-shi, Yamagata 990-9585, Japan
  • Hospital Clinic de Barcelona /ID# 227772
    Barcelona, 08036, Spain
  • Hospital Universitario Fundacion Jimenez Diaz /ID# 227771
    Madrid, 28040, Spain
  • Hospital Universitario Virgen de la Victoria /ID# 227770
    Malaga, 29010, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in May 2023, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 3, 2021
StartActual
Jun 25, 2021
Primary completionActual
May 9, 2023
CompletionActual
May 9, 2023
Last update
Feb 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04912063
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 3, 2021
Start date
Jun 25, 2021
Primary completion
May 9, 2023
Completion
May 9, 2023
Last update
Feb 26, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemzoparlimab

Start the discussion